Livingston Judith, Therrell Bradford L, Mann Marie Y, Anderson Carolyn Stady, Christensen Katherine, Gorski Jerome L, Grange Dorothy K, Peck Dawn, Roberston Margy, Rogers Sharmini, Taylor Maura, Kaye Celia I
Department of Pediatrics, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA,
J Community Genet. 2011 Dec;2(4):191-200. doi: 10.1007/s12687-011-0055-z. Epub 2011 Jul 6.
To determine how US newborn dried bloodspot screening (NDBS) programs obtain patient-level data on clinical genetic counseling services offered to families of newborns identified through newborn NDBS and the extent to which newborns and their families receive these services. These data should serve to inform programs and lead to improved NDBS follow-up services. Collaborations were established with three state NDBS programs that reported systematically tracking genetic counseling services to newborns and their families identified through NDBS. A study protocol and data abstraction form were developed and IRB approvals obtained. Data from three state NDBS programs on a total of 151 patients indicated that genetic services are documented systematically only by metabolic clinics, most often by genetic counselors. Data from 69 endocrinology patients indicated infrequent referrals for genetic services; as expected higher for congenital adrenal hyperplasia than congenital hypothyroidism. Endocrinology patients were often counseled by physicians. While systematic tracking of genetic counseling services may be desirable for quality assurance of NDBS follow-up services, current systems do not appear conducive to this practice. Clinical records are not typically shared with NDBS programs and tracking of follow-up clinical genetic services has not been generally defined as a NDBS program responsibility. Rather, tracking of clinical services, while recognized as useful data, has been viewed by NDBS programs as a research project. The associated IRB requirements for patient-related research may pose an additional challenge. National guidance for NDBS programs that define quality genetic service indicators and monitoring responsibilities are needed. US experiences in this regard may provide information that can assist developing programs in avoiding tracking issues.
为了确定美国新生儿干血斑筛查(NDBS)项目如何获取有关为通过新生儿NDBS筛查出的新生儿家庭提供的临床遗传咨询服务的患者层面数据,以及新生儿及其家庭接受这些服务的程度。这些数据应有助于为项目提供信息,并改善NDBS后续服务。与三个州的NDBS项目建立了合作关系,这些项目报告称系统地跟踪了为通过NDBS筛查出的新生儿及其家庭提供的遗传咨询服务。制定了研究方案和数据提取表,并获得了机构审查委员会(IRB)的批准。来自三个州NDBS项目的总共151名患者的数据表明,只有代谢诊所系统地记录了遗传服务,大多数情况下是由遗传咨询师记录的。来自69名内分泌科患者的数据表明,转介进行遗传服务的情况很少见;正如预期的那样,先天性肾上腺皮质增生症患者的转介率高于先天性甲状腺功能减退症患者。内分泌科患者通常由医生进行咨询。虽然对遗传咨询服务进行系统跟踪可能有助于NDBS后续服务的质量保证,但目前的系统似乎不利于这种做法。临床记录通常不会与NDBS项目共享,对后续临床遗传服务的跟踪通常未被定义为NDBS项目的职责。相反,虽然临床服务跟踪被认为是有用的数据,但NDBS项目将其视为一个研究项目。与患者相关研究相关的IRB要求可能会带来额外的挑战。需要为NDBS项目制定国家指南,以定义高质量遗传服务指标和监测责任。美国在这方面的经验可能会提供信息,帮助发展中的项目避免跟踪问题。